WO2008034122A3 - Hindered ester-based biodegradable linkers for oligonucleotide delivery - Google Patents

Hindered ester-based biodegradable linkers for oligonucleotide delivery Download PDF

Info

Publication number
WO2008034122A3
WO2008034122A3 PCT/US2007/078597 US2007078597W WO2008034122A3 WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3 US 2007078597 W US2007078597 W US 2007078597W WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3
Authority
WO
WIPO (PCT)
Prior art keywords
based biodegradable
hindered ester
oligonucleotide delivery
biodegradable linkers
linkers
Prior art date
Application number
PCT/US2007/078597
Other languages
French (fr)
Other versions
WO2008034122A2 (en
Inventor
Hong Zhao
Original Assignee
Enzon Pharmaceuticals Inc
Hong Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Hong Zhao filed Critical Enzon Pharmaceuticals Inc
Priority to JP2009528517A priority Critical patent/JP2010503707A/en
Priority to MX2009002859A priority patent/MX2009002859A/en
Priority to CA002662978A priority patent/CA2662978A1/en
Priority to EP07842576A priority patent/EP2063709A2/en
Priority to AU2007296054A priority patent/AU2007296054B2/en
Publication of WO2008034122A2 publication Critical patent/WO2008034122A2/en
Publication of WO2008034122A3 publication Critical patent/WO2008034122A3/en
Priority to IL197516A priority patent/IL197516A0/en
Priority to US12/402,743 priority patent/US8110559B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same.
PCT/US2007/078597 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery WO2008034122A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2009528517A JP2010503707A (en) 2006-09-15 2007-09-15 Hindered ester biodegradable linkers for oligonucleotide delivery
MX2009002859A MX2009002859A (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery.
CA002662978A CA2662978A1 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP07842576A EP2063709A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
AU2007296054A AU2007296054B2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
IL197516A IL197516A0 (en) 2006-09-15 2009-03-10 Ester-based polymeric delivery systems
US12/402,743 US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84502806P 2006-09-15 2006-09-15
US60/845,028 2006-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/402,743 Continuation US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Publications (2)

Publication Number Publication Date
WO2008034122A2 WO2008034122A2 (en) 2008-03-20
WO2008034122A3 true WO2008034122A3 (en) 2008-10-30

Family

ID=39184642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078597 WO2008034122A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Country Status (9)

Country Link
EP (1) EP2063709A2 (en)
JP (1) JP2010503707A (en)
KR (1) KR20090055623A (en)
CN (1) CN101534643A (en)
AU (1) AU2007296054B2 (en)
CA (1) CA2662978A1 (en)
IL (1) IL197516A0 (en)
MX (1) MX2009002859A (en)
WO (1) WO2008034122A2 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5814505B2 (en) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Pharmaceutical composition comprising antimiRNA antisense oligonucleotide
EP3431602A1 (en) 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
MX2009002854A (en) 2006-09-15 2009-03-27 Enzon Pharmaceuticals Inc Polyalkylene oxides having hindered ester-based biodegradable linkers.
US20100279408A1 (en) * 2006-11-27 2010-11-04 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (en) 2007-03-22 2013-09-30 Santaris Pharma As Short RNA antagonist compounds to modulate the desired mRNA
CA2685444A1 (en) 2007-05-01 2008-11-06 Jesper Worm Rna antagonist compounds for the modulation of beta-catenin
WO2008138904A2 (en) 2007-05-11 2008-11-20 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
RU2010116245A (en) 2007-09-24 2011-11-10 Ноксон Фарма Аг (De) NUCLEIC ACIDS BINDING C5a
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
US7737125B2 (en) 2007-11-26 2010-06-15 Enzon Pharamaceuticals, Inc. LNA antagonists targeting the androgen receptor
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009071082A2 (en) 2007-12-03 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pik3ca expression
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (en) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S MicroRNA-mediated modulation of colony stimulating factors
DK2328619T3 (en) * 2008-08-22 2017-03-13 Baxalta GmbH POLYMER BENZYL CARBONATE DERIVATES
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
NZ596608A (en) 2009-06-12 2014-01-31 Santaris Pharma As New potent anti apob antisense compounds
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
BR112012002280B1 (en) 2009-07-31 2020-04-07 Ascendis Pharma As water-insoluble hydrogel based on biodegradable polyethylene glycol, its preparation process, conjugate, vehicle-bound compound and pharmaceutical composition.
RU2556340C2 (en) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Long-acting insulin composition
PE20120918A1 (en) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland DEPTH DRUGS THAT INCLUDE AN INSULIN-CONNECTOR CONJUGATE
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
CN102906265B (en) 2010-04-21 2016-08-24 诺松制药股份公司 Lipid binding nucleic acid
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
ES2678497T3 (en) 2010-09-09 2018-08-13 Noxxon Pharma Ag Nucleic acids that bind to SDF-1 and its use in cancer treatment
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US20140057970A1 (en) 2010-10-29 2014-02-27 Frank Schwobel Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012066092A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of aurora kinase a expression
WO2012066093A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
EP2663640B1 (en) 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2012110457A2 (en) 2011-02-14 2012-08-23 Santaris Pharma A/S Compounds for the modulation of osteopontin expression
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
EP2723863A1 (en) 2011-06-23 2014-04-30 Stella ApS Hcv combination therapy
KR20140058536A (en) 2011-06-30 2014-05-14 스텔라 에이피에스 Hcv combination therapy
KR20140064765A (en) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv combination therapy
PL2581448T3 (en) * 2011-10-13 2015-08-31 Association Inst De Myologie Tricyclo-phosphorothioate DNA
WO2013056852A1 (en) 2011-10-21 2013-04-25 Noxxon Pharma Ag Glucagon binding nucleic acids
CA2853328A1 (en) 2011-11-07 2013-05-16 Stella Aps Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
EA201400566A1 (en) 2011-11-11 2014-09-30 Сэнтерис Фарма А/С CONNECTIONS INTENDED FOR MODELING SPLICING SMN2
ES2786007T3 (en) 2012-01-10 2020-10-08 Aptarion Biotech Ag New C5a-binding nucleic acids
MX2014008456A (en) 2012-01-10 2014-11-25 Noxxon Pharma Ag Nucleic acids specifically binding cgrp.
WO2013170963A2 (en) 2012-05-16 2013-11-21 Noxxon Pharma Ag Enzymatic synthesis of l-nucleic acids
MY173826A (en) 2012-11-15 2020-02-24 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
CN112263682A (en) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 Antisense oligomers and conjugates targeting PCSK9
US20170233737A1 (en) 2013-11-04 2017-08-17 Noxxon Pharma Ag Means and Methods for the Treatment of Nephropathy
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
GB201414098D0 (en) * 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
JP6689279B2 (en) 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス Chiral toxicity screening method
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
SG11201805026SA (en) 2016-01-08 2018-07-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
PL3400019T3 (en) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP3423103A1 (en) 2016-03-01 2019-01-09 Ascendis Pharma Bone Diseases A/S Pth prodrugs
EP3443095A1 (en) 2016-04-15 2019-02-20 Noxxon Pharma AG Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
EA201892467A1 (en) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Oligonucleotide Analogues Aimed at Human LMna
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
CN117257922A (en) 2016-09-29 2023-12-22 阿森迪斯药物骨疾病股份有限公司 PTH compounds with low peak-to-valley ratio
JP7039574B2 (en) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー／エス Release control PTH compound escalating dose setting
CN109843295B (en) 2016-09-29 2022-04-05 阿森迪斯药物生长障碍股份有限公司 Combination therapy with controlled release of CNP agonist
CN109789189B (en) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 Dosage regimen for controlled release of PTH compounds
JP7216006B2 (en) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド Hydrogel Crosslinked Hyaluronic Acid Prodrug Compositions and Methods
KR102141124B1 (en) 2018-01-30 2020-08-04 (주)바이오니아 Double-stranded Oligonucleotide Complex comprising Double― stranded miRNA and Uses thereof
AU2019246389A1 (en) 2018-03-28 2020-08-27 Ascendis Pharma Oncology Division A/S IL-2 conjugates
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
KR20210013584A (en) 2018-05-18 2021-02-04 아센디스 파마 본 디지즈 에이/에스 Initiating capacity of PTH conjugate
WO2019219723A1 (en) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treatment of microrna related diseases
SG11202101982RA (en) 2018-09-26 2021-03-30 Ascendis Pharma As Degradable hyaluronic acid hydrogels
AU2019350376A1 (en) 2018-09-26 2021-03-18 Ascendis Pharma A/S Treatment of infections
CA3114329A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
JP2022516308A (en) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Conjugate of pattern recognition receptor agonist
US20220054477A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
US20220054478A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
JP2022516314A (en) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Persistent topical drug levels for innate immune agonists
US20220088149A1 (en) 2019-02-11 2022-03-24 Ascendis Pharma Bone Diseases A/S Liquid Pharmaceutical Formulations of PTH Conjugates
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
US20230102309A1 (en) 2019-06-21 2023-03-30 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254611A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
EP4146281A1 (en) 2020-05-04 2023-03-15 Ascendis Pharma A/S Hydrogel irradiation
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
JP2023540701A (en) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Glycosylated IL-2 protein and its uses
CN112047840A (en) * 2020-08-31 2020-12-08 山东药品食品职业学院 Synthesis method of 7-bromo-2, 2-dimethylheptanoic acid ethyl ester and product obtained by synthesis
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
KR20230164709A (en) 2021-04-01 2023-12-04 아센디스 파마 에이에스 Use of long-acting growth hormone to treat inflammatory diseases
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
WO2023247651A1 (en) 2022-06-21 2023-12-28 TME Pharma AG Methods for treating a tumor in a subject

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
ATE399809T1 (en) * 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp METHOD FOR PRODUCING POLYMER CONJUGATES
JP3485023B2 (en) * 1999-05-20 2004-01-13 東亞合成株式会社 Nucleoside compound
WO2001078784A1 (en) * 2000-04-15 2001-10-25 Kolon Industries, Inc. Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
JP2004518776A (en) * 2000-12-01 2004-06-24 エンゾン，インコーポレーテッド Tetrapartate prodrug
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
AU2004230927B9 (en) * 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
MX2009002854A (en) * 2006-09-15 2009-03-27 Enzon Pharmaceuticals Inc Polyalkylene oxides having hindered ester-based biodegradable linkers.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same

Also Published As

Publication number Publication date
WO2008034122A2 (en) 2008-03-20
EP2063709A2 (en) 2009-06-03
AU2007296054A1 (en) 2008-03-20
CN101534643A (en) 2009-09-16
CA2662978A1 (en) 2008-03-20
MX2009002859A (en) 2009-03-30
IL197516A0 (en) 2009-12-24
JP2010503707A (en) 2010-02-04
KR20090055623A (en) 2009-06-02
AU2007296054B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2008034122A3 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
WO2006020768A3 (en) Chemically modified oligonucleotides
HK1211179A1 (en) Immunostimulatory oligonucleotide multimers
EP1981544A4 (en) Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2076326A4 (en) Ce-zr-r-o catalysts, articles comprising the ce-zr-r-o catalysts and methods of making and using the ce-zr-r-o catalysts
EP2032470A4 (en) Biodegradable compositions, articles prepared from biodegradable compositions and manufacturing methods
WO2007121131A3 (en) Medical devices including shape memory materials
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
HK1201185A1 (en) Peroxide removal from drug delivery vehicle
EP1942831A4 (en) Twist-down implant delivery technologies
EP1991688A4 (en) Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol
WO2008034007A3 (en) Medical devices
EP1915449A4 (en) Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
GB0402131D0 (en) Delivery method
IL206395A (en) N-heterocyclyl-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and pharmaceutical compositions comprising them
HK1112427A1 (en) Drug delivery compositions and related methods
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2007121318A3 (en) Formulations for delivering insulin
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
EP1723162A4 (en) Anti-microrna oligonucleotide molecules
EP2158254A4 (en) Poly(organophosphazene) hydrogels for drug delivery, preparation method thereof and use thereof
EP2063816A4 (en) Implants comprising biodegradable metals and method for manufacturing the same
WO2007143086A3 (en) Delivery method
EP2076557A4 (en) Polylysine dendrimer contrast agent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041936.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842576

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 435/MUMNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2662978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002859

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528517

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007296054

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842576

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097007157

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007296054

Country of ref document: AU

Date of ref document: 20070915

Kind code of ref document: A